Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

No longer available 1Completed 1

Sponsor Class

INDUSTRY 2

Study Type

Interventional 1Expanded_access 1

Sponsor

Cancer Type

Gastrointestinal 2

Conditions

Cholangiocarcinoma 4Liver Neoplasms 3Biliary Tract Neoplasms 3Bile Duct Neoplasms 2Acrocephalosyndactylia 2Urinary Bladder Neoplasms 1Stomach Neoplasms 1Neoplasms 1Carcinoma, Transitional Cell 1

Interventions

Gemcitabine 40Cisplatin 24Capecitabine 21Fluorouracil 19Oxaliplatin 17Leucovorin 14pembrolizumab 9Irinotecan 8Radiotherapy 7Erlotinib Hydrochloride 7durvalumab 6Sorafenib 4Photochemotherapy 4Magnetic Resonance Spectroscopy 4Carboplatin 4trametinib 3Trastuzumab 3Radiofrequency Ablation 3Long-Term Synaptic Depression 3Interleukin-12 Subunit p35 3Filgrastim 3Drug Therapy 3Dihematoporphyrin Ether 3Dexamethasone 3Cholangiopancreatography, Endoscopic Retrograde 3Chemotherapy, Adjuvant 3trifluridine tipiracil drug combination 2tivozanib 2tislelizumab 2spartalizumab 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Bile Duct Neoplasms × derazantinib × Clear all
NCT04087876 2025-04-06

Expanded Access Use of Derazantinib for Advanced Intrahepatic Cholangiocarcinoma (iCCA) With FGFR Genomic Alterations

Basilea Pharmaceutica

No longer available
Gastrointestinal

Bile Duct Neoplasms, Biliary Tract Neoplasms, Liver Neoplasms, Cholangiocarcinoma

NCT03230318 2023-12-19

FIDES-01

Basilea Pharmaceutica

Phase 2 Completed
148 enrolled 15 charts
Gastrointestinal

Bile Duct Neoplasms, Biliary Tract Neoplasms, Liver Neoplasms, Cholangiocarcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡